Collects royalties from GSK respiratory drugs and owns infectious-disease drugs including Xacduro for pneumonia.
Collects royalties from GSK respiratory drugs and owns infectious-disease drugs including Xacduro for pneumonia.
Receives a share of GSK's sales of its respiratory inhalers with none of the selling costs, since GSK sells the medicines; the rights stem from Innoviva's origin as Theravance, which developed them with GSK. Xacduro, an infection medicine, came with its 2022 purchase of Entasis.
Moat: narrow (IP / patents). Long-dated royalty contracts on GSK blockbuster respiratory drugs provide durable cash flow.
Headquarters: Waltham, Massachusetts, US · Founded: 1994 · Employees: 159
Size Innoviva (INVA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 2061st largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.40 on 18 Nov 2026.
Performance Over six months the shares fell 17.3%, against -19.0% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 12.4% over the last twelve months (peer median +7.6%); the operating margin is 37.6% (peer median 0.8%).
Valuation It trades at 9.5× forward earnings against a peer median of 18.2× (2nd cheapest of 11).
Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.7 points above its cost of capital (6.7% WACC).
Short interest Short interest is 10.5% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $452M | $425M | $373M | $324M | $345M |
| Revenue growth | — | +14% | +15% | -6% | — |
| Gross profit | $326M | $308M | $296M | $246M | $312M |
| EBITDA | $211M | $204M | $207M | $150M | $227M |
| Net income | $193M | $271M | $23.4M | $180M | $214M |
| Free cash flow | $183M | $196M | $188M | $141M | $202M |
| Capital expenditure | $955,000 | $1.13M | $4.27M | $411,000 | $67,000 |
| Total debt | $270M | $269M | $451M | $449M | $615M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Innoviva INVA | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% |
| Royalty Pharma RPRX | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INVA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.5% | -4.1% | 3rd lowest of 20 |
| 6-month return | -17.3% | -19.0% | 10th highest of 20 |
| Distance from 52-week high | -26.8% | -38.9% | 4th highest of 20 |
| Revenue growth (TTM) | +12.4% | +7.6% | 7th highest of 16 |
| Operating margin | 37.6% | 0.8% | highest of 16 |
| Forward P/E | 9.5× | 18.2× | 2nd cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | -17.2% | 3.4% | least demanding of 8 |
| Growth delivered (Del g) | +3.9% | +18.1% | 2nd lowest of 8 |
| Hurdle (Req g minus delivered) | -21.1 pp | -13.0 pp | 2nd least demanding of 8 |
| ROIC minus cost of capital | +9.7 pp | -3.3 pp | highest of 16 |
| EV / EBITDA | 4.7× | n/a | — |
| Net debt / EBITDA | -1.5× | 2.2× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |